{'fraction_non_alphanumeric': 0.03550295857988166, 'fraction_numerical': 0.004733727810650888, 'mean_word_length': 6.356521739130435, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunomodulatory treatment of multiple sclerosis in Norway

Objectives and methods – National guidelines for immunomodulatory treatment in multiple sclerosis (MS) were established in Norway in 2001. However, the nation‐wide treatment practice has not been evaluated since. We therefore obtained information of all patients who have received prescriptions for the approved immunomodulatory medications, interferon‐beta (Betaferon®, Avonex®, Rebif®) and glatiramer acetate (Copaxone®) registered in the Norwegian Prescription Database (Reseptregisteret). We also made a survey of patients treated with mitoxantrone (Novantrone®) as well as patients supplied with immunomodulatory drugs in treatment trials. To further calculate the treatment frequency, a nation‐wide prevalence of MS in Norway was estimated, based on available prevalence studies.